Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg anti-HBE). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Ask to speak with the on-call infectious diseases registrar if you or your doctor are telephoning the hospital.Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.Infectious Diseases, the Royal Melbourne Hospital External Link.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |